Adipose mesenchymal stromal cell therapy in a desperate case of right-hand ischemia

Álvarez, Andrés Eduardo Salazar; Arranz, Mariano García; Moral, Luis Riera del; Azcona, Covadonga Mendieta; Ramírez, I. Leblic; Heredero, Álvaro Fernández

doi:10.1016/j.jcyt.2016.03.297

Cited by 3 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many angiogenic molecules have been described in both animal and human models with ischemic diseases ( Freedman & Isner, 2002 ; Heijnen & Van der Sluijs, 2015 ; Domouzoglou et al, 2015 ). The use of different stem cells such as those derived from hematopoietic tissue, fetal membrane and mesenchymal tissue has also been postulated ( Ishikane et al, 2008 ; Shibata et al, 2008 ; Salazar Álvarez et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

“…Among the mesenchymal cells, stem cells derived from adipose tissue (ASCs) are interesting candidates for this purpose because they can be obtained in a non-aggressive way, have a privileged immunological profile, are multipotent, and have shown safety in both autologous and allogeneic use, in both experimental and clinical trials in Phases I/IIa, for the treatment of ischemic diseases ( Zuk et al, 2002 ). ASCs can secrete angiogenic, immunomodulatory, and cellular survival factors that have been shown to be effective in the treatment of atherosclerosis and diabetic complications both in animal and human models ( Iwase et al, 2005 ; Shibata et al, 2008 ; Kim et al, 2006 ; Salazar Álvarez et al, 2016 ; Zuk et al, 2002 ). Mesenchymal cells derived from subjects with cardiovascular and diabetic disease are less effective ( Capla et al, 2007 ; Loomans et al, 2004 ; Thum et al, 2007 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue

García¹,

Gómez-Heras

Moral

et al. 2017

PeerJ

Self Cite

View full text Add to dashboard Cite

BackgroundDiabetes is one of the major risk factors for peripheral arterial disease. In patients in whom surgery cannot be performed, cell therapy may be an alternative treatment. Since time is crucial for these patients, we propose the use of allogenic mesenchymal cells.MethodsWe obtained mesenchymal cells derived from the fat tissue of a healthy Sprague-Dawley rat. Previous diabetic induction with streptozotocin in 40 male Sprague-Dawley rats, ligation plus left iliac and femoral artery sections were performed as a previously described model of ischemia. After 10 days of follow-up, macroscopic and histo-pathological analysis was performed to evaluate angiogenic and inflammatory parameters in the repair of the injured limb. All samples were evaluated by the same blind researcher. Statistical analysis was performed using the SPSS v.11.5 program (P < 0.05).ResultsSeventy percent of the rats treated with streptozotocin met the criteria for diabetes. Macroscopically, cell-treated rats presented better general and lower ischemic clinical status, and histologically, a better trend towards angiogenesis, greater infiltration of type 2 macrophages and a shortening of the inflammatory process. However, only the inflammatory variables were statistically significant. No immunological reaction was observed with the use of allogeneic cells.DiscussionThe application of allogeneic ASCs in a hind limb ischemic model in diabetic animals shows no rejection reactions and a reduction in inflammatory parameters in favor of better repair of damaged tissue. These results are consistent with other lines of research in allogeneic cell therapy. This approach might be a safe, effective treatment option that makes it feasible to avoid the time involved in the process of isolation, expansion and production of the use of autologous cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue

García¹,

Gómez-Heras

Moral

et al. 2017

PeerJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…The exact mechanism of improved perfusion isn't well known, but secretion of large amount of cytokines like endothelial growing factor on ischemic conditions, the vasculogenesis promoted by endothelial progenitor cells and the anti-inflammatory and immune modulating properties of these cells [18] might be responsible for the clinical response [19]. These different factors might explain the early relieve of pain and the improvement of vascularization at medium and large term [20]. Adipose mesenchymal cells have de advantage of being easy to obtain with low risks for the patient [21][22][23], but there is still a lot of room to improve when we talk about severe ill patients with lots of comorbidities, as it uses to be in Vascular Surgery field.…”

Section: Discussionmentioning

confidence: 99%

Allogeneic Adipose Mesenchymal Stem Cell Therapy in a Desperate Case of Forearm and Hand Ischemia

L¹,

Álvarez²

2018

IJST

View full text Add to dashboard Cite

“…Many angiogenic molecules have been described in both animal and human models with ischemic diseases (Freedman and Isner, 2002;Heijnen and van der Sluijs, 2015;Domouzoglou et al, 2015). The use of different stem cells such as those derived from hematopoietic tissue, fetal membrane and mesenchymal tissue has also been postulated (Ishikane et al, 2008;Shibata et al, 2008;Álvarez et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue

García

Gómez-Heras

Moral

et al. 2017

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Diabetes is one of the major risk factors for peripheral arterial disease. In patients in whom surgery cannot be performed, cell therapy may be an alternative treatment. Since time is crucial for these patients, we propose the use of allogenic mesenchymal cells. Methods: We obtained mesenchymal cells derived from the fat tissue of a healthy Sprague-Dawley rat. Previous diabetic induction with streptozotocin in 40 male Sprague-Dawley rats, ligation plus left iliac and femoral artery sections were performed as a previously described model of ischemia. After 10 days of follow-up, macroscopic and histo-pathological analysis was performed to evaluate angiogenic and inflammatory parameters in the repair of the injured limb. All samples were evaluated by the same blind researcher. Statistical analysis was performed using the SPSS v.11.5 program (p <0.05). Results: Seventy percent of the rats treated with streptozotocin met the criteria for diabetes. Macroscopically, cell-treated rats presented better general and lower ischemic clinical status, and histologically, a better trend towards angiogenesis, greater infiltration of type 2 macrophages and a shortening of the inflammatory process. However, only the inflammatory variables were statistically significant. No immunological reaction was observed with the use of allogeneic cells. Discussion: The application of allogeneic ASCs in a hind limb ischemic model in diabetic animals shows no rejection reactions and a reduction in inflammatory parameters in favor of better repair of damaged tissue. These results are consistent with other lines of research in allogeneic cell therapy. This approach might be a safe, effective treatment option that makes it feasible to avoid the time involved in the process of isolation, expansion and production of the use of autologous cells.

show abstract

Adipose mesenchymal stromal cell therapy in a desperate case of right-hand ischemia

Cited by 3 publications

References 13 publications

The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue

The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue

Allogeneic Adipose Mesenchymal Stem Cell Therapy in a Desperate Case of Forearm and Hand Ischemia

The effects of allogenic stem cells in a murine model of hind limb diabetic ischemic tissue

Contact Info

Product

Resources

About